Tony J. Hunt was named our President and Chief Executive Officer and has served on our Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to our Board of Directors his deep understanding of the bioprocessing market.
Jon K. Snodgres joined Repligen in July 2014 as our Chief Financial Officer, where he oversees financial operations for the Company. Mr. Snodgres was previously with Maquet Cardiovascular, a medical device company, where he served as CFO for five years. At Maquet, in addition to being responsible for the preparation and oversight of the company’s financial statements, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a B.S. in Business Administration, Finance from Northern Arizona University.
Ralf Kuriyel joined Repligen in October 2016 as our Senior Vice President, Research and Development where he oversees the Company’s research and development efforts. Mr. Kuriyel was previously Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation, whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and
has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration
Marc J. Centrella于2018年5月加入Repligen，担任业务开发和战略副总裁。 加入Repligen之前，Centrella先生曾在医疗器械公司BD工作，作为业务开发 & 战略团队的高级主管，他帮助执行了多项战略性和变革性的并购交易，包括BD以240亿美元收购C.R.Bard以及与Apax Partners合资创立了BD的呼吸系统解决方案。2015年加入BD之前，Centrella先生曾在Catalent Pharma Solutions担任公司发展总监，负责寻求并实施了一系列战略性的收购，并最终于2014年成功促成了公司的IPO。2005至2013年，Centrella先生在德意志银行和美国银行美林担任投资银行家，负责金融机构客户业务。Centrella先生于2004年获得新泽西州拉马波学院工商管理、金融学士学位。
Gautam Choudhary joined Repligen in November 2018 as Vice President and General Manager of Bioprocess Systems and Automation. He is responsible for building the infrastructure and developing the strategy for TFF systems and advancing workflows for continuous manufacturing. Before coming to Repligen, Gautam worked at Lonza supporting strategic and operational projects and developing the go-to-market strategy for Cell and Gene Therapy for Bioscience Solutions. Prior to Lonza, he spent twelve years at Life Technologies/Thermo Fisher leading the Cell Culture (Gibco) business for Bioproduction. Before joining Life, he held several technical and commercial roles at Millipore in Asia and Europe supporting filtration, chromatography and the systems business. Mr. Choudhary holds a Bachelor's Degree in Mechanical Engineering and an MBA in Marketing from Leeds University, UK.
John Connors于2016年12月作为副总裁加入Repligen，负责公司位于马萨诸塞州什鲁斯伯里的TangenX业务。 此前，Connors先生是TangenX公司的总裁，该公司于2004年成立，致力于开发和生产领先的切向流过滤（TFF）产品。在TangenX工作期间，Connors先生和他的团队将第一款针对一次性使用而特制的TFF膜包推向了市场。在过去23年间，Connors先生一直在生物工艺和生命科学行业工作，包括Pall Filtron、Becton Dickinson以及TangenX。在他整个生命科学行业的职业生涯中，Connors先生在制造、产品设计/工程和公司管理领域担任领导角色。他拥有马萨诸萨州伍斯特理工学院机械工程理学学士学位。
Ken Elmer于2016年11月加入Repligen。他拥有超30年的专业服务行业、IT服务和管理咨询经验。 Ken曾在多个国家、多个行业的高增长、创业型企业工作，包括制造业、保险、金融服务、生命科学、分销和电讯。最近，Ken是Attune Consulting的首席人力资源官，其是一家全球化的SAP服务供应商。在此之前，他曾在Celerant Consulting，一家运营管理咨询公司，担任人力资源高级副总裁一职。其它领导职务还包括GlassHouse Technologies的人力资源副总裁、Viant公司的首席人力官以及Cambridge Technology Partners的HR副总裁，在过去九年内，他担任过多个领导角色，包括在爱尔兰和瑞士开展业务。
副总裁，细胞培养 / 层析
Rachel Goodrich was named Vice President of Marketing in March 2017 after joining Repligen in January 2015. She rebranded Repligen as a bioprocessing company, developed and launched the Repligen website, implemented high ROI tools for the commercial organization from innovative Marketing-On-Demand to targeted technical roadshows and webinars, building out an organization covering strategic marketing, market research, digital marketing and marketing communications. Prior to joining Repligen, she was Market Development Leader for the Bioproduction Division of LIFE Technologies/ Thermo Fisher Scientific/ Applied Biosystems, responsible for global market development and marketing programs for four franchise business units, and was the recipient of numerous Marketing Excellence Awards. She holds a Bachelor's degree in Economics from the University of the Philippines, a Master's Degree in Economics and a Master's Degree in Education from Stanford University.
高级副总裁，超滤 / 洗滤
副总裁，运营 - Repligen 瑞典
Gustav Silfversparre于2013年3月被任命为Repligen的运营副总裁，管理Repligen位于瑞士隆德的生产基地。 加入Repligen之前，Silfversparre先生是Novozymes Biopharma AB的运营总监，该公司于2011年12月被Repligen收购。2008-2010年间，Silfversparre先生曾是生物药协调委员会的负责人，其是Novozymes内部生物药领域的一个全球项目和生产协调功能。从2002至2008年，Silfversparre先生是Novozymes Biopharma AB开发部门的负责人。Silfversparre先生拥有皇家理工学院生物技术证书和隆德大学工程学院化学工程硕士学位。
Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth, a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves as a member on the board of directors of Assertio Therapeutics, Inc. and Medicines360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board of Directors include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.
Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 25 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy currently serves on the board of directors of Fluidigm, 908 Devices and Biocare Medical. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board of Directors include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.
Glenn L. Cooper, M.D. has served as a director of Repligen since August 2009. Dr. Cooper served as Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. Prior to that, Dr. Cooper served as the Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on urology and endocrinology, from 2000 to 2009 and as Chief Executive Officer and Director from 1993 to 2000. Prior to joining Indevus in 1993, Dr. Cooper held numerous executive level positions including President and Chief Executive Officer of Progenitor, Inc., Executive Vice President and Chief Operating Officer of Sphinx Pharmaceuticals Corporation, and various clinical and regulatory positions with Eli Lilly and
Company. Dr. Cooper has participated in the development, approval and commercialization of numerous drugs including Prozac®, Axid®, Lorabid®, Ceclor®, SANCTURA®, SANCTURA XR®, Supprelin-LA® and Vantas®. Dr. Cooper received an M.D. from Tufts University School of Medicine, performed his postdoctoral training in Internal Medicine and Infectious Diseases at the New England Deaconess Hospital and the Massachusetts General Hospital and received a B.A. from Harvard College. Dr. Cooper also serves as the Chairperson of the board of directors of Lascaux Media, LLC, a privately-held company. Dr. Cooper’s qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies.
John G. Cox has served as a director of Repligen since November 2013. Mr. Cox was most recently the CEO of Bioverativ Inc., a company which spun out of Biogen, Inc. in 2017, was publicly-traded and was then acquired by Sanofi in February 2018. Previously, he was the Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc., a position he held since June 2010. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen’s operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000 to 2003, Mr. Cox held a number of senior operational roles at biotech contract manufacturer Covance/Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC from 1993 to 2000. He currently serves as Executive Chairman at Torque Therapeutics, a cellular immuno-oncology company. Mr. Cox holds an MBA from the University of Michigan, an M.S. in Cell Biology from California State University and a B.S. in Biology from Arizona State University. Mr. Cox’s qualifications to sit on the Company’s Board of Directors include his extensive experience in biopharmaceutical manufacturing and as a biopharmaceutical executive.
Tony J. Hunt was named our President and Chief Executive Officer and has served on our Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in
Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to our Board of Directors his deep understanding of the bioprocessing market.
Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venturebacked single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir serves on the board of directors of the medical technology company Neuronetics, Inc. and life science company G1 Therapeutics, Inc. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board of Directors include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.
Thomas F. Ryan Jr. has served as a director of Repligen since September 2003. Mr. Ryan is currently an investor in various private companies. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a director for the New York State Independent System Operator and a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.